期刊文献+

抗VEGFR-2 scFv-Fc融合抗体的构建及其在CHO细胞中的稳定表达 被引量:4

Construction of Anti-VEGFR-2 scFv-Fc Fusion Antibody and Stable Expression in CHO-k Cells
原文传递
导出
摘要 目前报道的靶向VEGF/VEGFR基因工程抗体多为不含Fc片段的Fabs、cFv等小分子抗体,该文旨在CHO-k细胞中表达抗VEGFR-2 scFv-Fc融合抗体。将抗VEGFR-2 scFv(AK404)基因与含有人IgG1恒定区的真核表达载体pcDNA3.1-Fc连接,重组质粒测序后经脂质体介导转染CHO-k细胞,G418加压筛选获取稳定表达细胞株。RT-PCR、western blot检测目的基因的转录、表达。测序结果表明重组质粒构建成功,RT-PCR及western blot显示目的基因成功整合到宿主基因组并表达。最终获得可稳定表达抗VEGFR-2 scFv-Fc融合抗体的重组CHO-k细胞株,为融合抗体的大量制备和活性研究打下基础。 Most of the reported engineering antibodies that target VEGF/VEGFR signaling pathway are truncated ones,such as Fab and scFv,which lack Fc fragment.The purpose of this article was to produce anti-VEGFR-2 scFv-Fc fusion antibody in CHO-k cells.Firstly,anti-VEGFR-2 scFv(AK404) gene was ligated with eukaryotic vector pcDNA3.1-Fc which yielded pcDNA3.1-scFv-Fc.After DNA sequencing,CHO-k cells were transfected with the recombinant plasmid by lipofectin according to the manufacturer's protocol.Then the stable expression cells were obtained by stressing selection with G418,and transcription and expression were examined by RT-PCR and Western blot respectively.DNA sequencing confirmed that the recombinant plasmid was successfully constructed.RT-PCR and Western blot showed that the target gene was integrated to the genome of the host cells and expressed accordingly.Finally,a recombinant CHO cell line that can express anti-VEGFR-2 scFv-Fc fusion antibody was obtained and propagated stably to generation 25.This study gives solid evidences to following researchers in pilot studies.
出处 《药物生物技术》 CAS CSCD 2011年第3期206-210,共5页 Pharmaceutical Biotechnology
基金 重大专项(2009ZX09503) 国家自然科学基金(81072561) 江苏省自然科学基金(BK2009299)
关键词 VEGFR-2 scFv-Fc融合抗体 抗肿瘤血管生成 Vascular endothelial growth factor receptor 2 scFv-Fc fusion antibody Anti-tumor angiogenesis
  • 相关文献

参考文献8

  • 1Folkman J. Antiangiogenesis in cancer therapy- endostatin and its mechanism if action [J]. Experimental Cell Re- search, 2006,321 (5): 594.
  • 2Andreas B. Recent developments in the inhibition of angio- genesis: examples from studies on platelet factor- 4 and the VEGF/VEGFR system [J]. Biochemical Pharmacology, 2004, 68 (4):1017.
  • 3Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF RECEPTOR- 2 (tim/KDR) as an anti- angiogenic therapeutic strategy [J]. Cancer Metastasis Rev ,1998,17(2):155.
  • 4Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2 [J]. Biochemical and Biophysical Research Communications, 2006,345 ( 1 ) : 438.
  • 5Zhang J, Li HX, Chen W, et al. Preparation of extracellular domain 3 of human vascular endothelial growth factor (VEGF) Receptor - 2 and the monitoring of its real-time binding to VEGF by blosensors [J]. Biotechnol Progr, 2009,25: 1703.
  • 6李海鑫,张娟,钱永军,陆文杰,林旭升,周雅琼,王旻.抗血管内皮生长因子受体2单链抗体的筛选及表达纯化[J].药物生物技术,2009,16(5):399-403. 被引量:4
  • 7吴本传,陈昭烈,刘红,郝振明,刘兴茂,黄培堂.采用定点整合表达技术构建t-PA表达CHO工程细胞株[J].药物生物技术,2004,11(4):221-224. 被引量:5
  • 8Jill M C, Tina S, Pam H N, et al. Condon engineering for improved antibody expression in mammalian cells [J]. Pro- tein Expression and Purification, 2007,55 (2) :279.

二级参考文献16

  • 1韩素文 俞炜源 李秀珍 等.培养细胞分泌血纤维蛋白溶酶原激活物的研究[J].军事医学科学院院刊,1987,11(2):101-101.
  • 2Andersen D C,Krummen L.Recombinant peotein expression for therapeutic application[J].Curr opin Biotechnol,2002,13(2):117.
  • 3Sauer B.Site-specific recombination:developments and application[J].Curr opin Biotechnol,1994,5(5):521.
  • 4Buchholz F,Ringrose L,Angrand P O,et al.Different thermostabilities of FLP and Cre recombinases:Implications for applied site-specific recombination [J].Nuc Acids Res,1996,24(21):4256.
  • 5萨姆布鲁克J 弗里奇EF 曼尼阿蒂斯T 金冬雁 黎孟枫译.分子克隆实验指南[M]·第二版[M].北京:科学出版社,1996..
  • 6Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor[J]. Biochem Bioph ys Res Commun, 1992,187(3) : 1579.
  • 7Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor[J]. Endocr Rev, 1997, 18(1): 4.
  • 8Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface[J]. Science, 1985, 228(4705) : 1315.
  • 9Scott JK, Smith GP. Searching for peptide ligands with an epitope library[J]. Science, 1990, 249(4967): 386.
  • 10Ferrara N, Frantz G, LeCouter J, et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries[J]. Am J Pathol, 2003, 162(6) : 1881.

共引文献7

同被引文献46

  • 1吴本传,陈昭烈,刘红,郝振明,刘兴茂,黄培堂.采用定点整合表达技术构建t-PA表达CHO工程细胞株[J].药物生物技术,2004,11(4):221-224. 被引量:5
  • 2Wahl O, Oswald M,Tretzel L,et al. Inhibition of Tumor Angiogen- esis hy Antibodies, Synthetic Small Molecules and Natural Prod- ucts[ J]. Curr Med Chem,2011 ,(18) :3136.
  • 3Amin DN, Bielenberg DR,Lifshits E,et al. Targeting EGFR acti-vity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells[ J]. Microvasc Res ,2008, ( 76 ) : 15.
  • 4Bocci G, Fioravanti A, Motta CL,et al. Antiproliferative and pro- apoptotic activity of CLM3,a novel multiple tyrosine kinase inhi- bitor,alone and in combination with SN-38 on endothelial and cancer cells [ J ]. Biochem Pharmacol, 2011, ( 81 ) : 1309.
  • 5Saharinen P, Eklund L, Pulkki K,et al. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis [ J ]. Trends Mol Med,2011,17 ( 7 ) :347.
  • 6Ghosh S, Maity P. Augmented antitumor effeets of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma ceils [ J ]. Int Immunopharmacol,2007, (7) : 1598.
  • 7Redondo P, Bandres E, Solano T, et al. Vascular Endothelial Growth Factor (VEGF) and Melanoma. N-acetylcysteine Down- regulates VEGF Production in vitro [ J ]. Cytokine, 2000, 12 (4) :374.
  • 8Bender JG,Yamashiro D J, Fox E. Clinieal Development of VEGF Signaling Pathway lnhibitors in Childhood Solid Tumors[ J ]. The Oncologist ,2011, (16) : 1614.
  • 9Zhang J, Li HX, Wang XY, et al. Phage-Derived Fully Human Antibody scFv Fragment Directed Against Human Vascular Endo- thelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF[ J]. Biotechnol Prog,2012,28(4) :981.
  • 10Youssoufian H, Hicklin DJ, Rowinsky EK. Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy [ J ]. Clin Cancer Res ,2007 ( 13 ) :5544.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部